The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Source: [Inc.](https://www.inc.com/rachel-suleymanov/nobel-prize-winner-startup-raised-350-million-dollars-now-cant-fund-cancer-programs/91416317)